Lead Product(s): PAT-1251
Therapeutic Area: Genetic Disease
Highest Development Status: Phase II Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 07, 2020
The two firms will combine & put in robust fibrosis and cancer services, including a recently inhaled galectin-3 modulator ph IIb for the potential treatment of idiopathic pulmonary fibrosis.